Stay updated on Pembrolizumab + Elbasvir/Grazoprevir Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Elbasvir/Grazoprevir Clinical Trial page.

Latest updates to the Pembrolizumab + Elbasvir/Grazoprevir Clinical Trial page
- CheckyesterdayChange DetectedThe page's revision indicator was updated from v3.3.3 to v3.3.4. This appears to be a metadata update with no visible changes to study content.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedAdded a Locations section showing Houston, Texas as a study site. The update also updates the revision from v3.3.2 to v3.3.3 and removes the old 'Texas Locations' header as well as the HHS Vulnerability Disclosure link.SummaryDifference0.2%

- Check51 days agoChange DetectedRevision label updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check58 days agoChange DetectedRemoval of the government funding delay banner from the page; this does not affect the study details or trial data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check73 days agoChange DetectedAdministrative updates to the study record, including a newer last update date and results posting information, with no changes to the study design or eligibility criteria.SummaryDifference0.4%

- Check101 days agoChange DetectedAdded a government-status notice and a v3.2.0 revision; removed the v3.1.0 revision. The page now informs users about potential delays and where to check current operating status, and indicates the new version.SummaryDifference2%

Stay in the know with updates to Pembrolizumab + Elbasvir/Grazoprevir Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Elbasvir/Grazoprevir Clinical Trial page.